Charles River Laboratories Intl (CRL) Stock Price, Quote & News

Company Profile

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of serv...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 781 222 6000

Website: www.criver.com

Address:

251 Ballardvale Street, Wilmington, United States

Estimize Feb. 23 at 3:00 PM

Wall St is expecting 1.93 EPS for $CRL Q1 [Reporting 05/07 BMO] http://www.estimize.com/intro/crl?chart=historical&metric_name=eps&utm_cont

0 · Reply

SuperGreenToday Feb. 23 at 10:04 AM

$CRL Share Price: $169.00 Contract Selected: Jul 17, 2026 $160 Calls Buy Zone: $18.79 – $23.21 Target Zone: $33.31 – $40.71 Potential Upside: 67% ROI Time to Expiration: 143 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Fletcher_13 Feb. 20 at 6:40 PM

$CRL 545k vol, staying flat until it commits toward 200.46 or rolls over

0 · Reply

RunnerSignals Feb. 20 at 11:31 AM

oversold bounce radar https://stocksrunner.com/news/2026-02-20-oversold-stocks-to-watch-today $CRL $ULS $ETSY $SMWB $PINS starting to wake up off the lows. setups getting interesting

0 · Reply

koditrump Feb. 18 at 7:19 PM

$CRL

0 · Reply

d_risk Feb. 18 at 3:53 PM

$CRL - Charles River Laboratories International Inc - 10K - Updated Risk Factors CRL flags new risks from deploying AI, a disruptive board-led strategic review (with possible deals, divestitures, and volatility), intensifying trade protectionism and tariffs, a major goodwill and intangible write-down in Biologics/Cell & Gene units, and regulatory moves to phase out animal testing that could pressure its core model. #BiotechIndustry #AIRisks #StrategicReview #TradeProtectionism #RegulatoryChanges 🟢 Added 🟠 Removed https://d-risk.ai/CRL/10-K/2026-02-18

0 · Reply

ZacksResearch Feb. 18 at 3:07 PM

$CRL beats Q4 estimates but shares dip — what gives? 🤔 📉 Adjusted EPS of $2.39 beats by 2.51%, yet shares fell 0.8% pre-market 📊 Revenues also topped estimates, despite a slight organic decline in revenues Understand the full picture here 👉 https://www.zacks.com/stock/news/2871047/crl-stock-down-despite-q4-earnings-revenue-beat-margins-rise?cid=sm-stocktwits-2-2871047-body-34009&ADID=SYND_STOCKTWITS_TWEET_2_2871047_BODY_34009

0 · Reply

ZacksResearch Feb. 18 at 1:11 PM

$CRL beats on earnings and revenue… yet the stock drops? 🤔 Q4 delivered an earnings and revenue beat, and margins actually rose — but shares are still under pressure. When a company posts solid numbers and the market sells it anyway, there’s usually more beneath the surface. Is this a short-term shakeout or a warning sign? Get the full breakdown here 👉 https://www.zacks.com/stock/news/2871047/crl-stock-down-despite-q4-earnings-revenue-beat-margins-rise?cid=sm-stocktwits-2-2871047-teaser-33919&ADID=SYND_STOCKTWITS_TWEET_2_2871047_TEASER_33919

0 · Reply

StocktwitsEarnings Feb. 18 at 12:21 PM

$CRL Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$5.62 down -33.18% YoY • Reported revenue of $994.23M down -0.83% YoY • Charles River Laboratories expects 2026 organic revenue growth to be (1.0)% to At Least Flat, and non-GAAP EPS is estimated to be $10.70-$11.20, an increase of approximately 4% to 9%.

0 · Reply

Estimize Feb. 18 at 11:00 AM

$CRL reported - EPS and - revenue for Q4. http://www.estimize.com/intro/crl?chart=historical&metric_name=eps&utm_content=CRL&utm_medium=act

0 · Reply

Charles River Laboratories International, Inc. (CRL) Q4 2025 Earnings Call Transcript

Feb 18, 2026, 11:20 AM EST - 5 days ago

Charles River Laboratories Q4 Review: Approaching A Bottom

Feb 18, 2026, 7:54 AM EST - 5 days ago

Charles River forecasts upbeat 2026 profit on improved demand for drug development services

Feb 18, 2026, 7:01 AM EST - 5 days ago

Charles River Laboratories Announces Executive Appointments

Feb 18, 2026, 7:00 AM EST - 5 days ago

Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance

Feb 12, 2026, 11:54 AM EST - 10 days ago

Halper Sadeh LLC Encourages Charles River Laboratories International, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Jan 21, 2026, 4:30 PM EST - 4 weeks ago

Charles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call

Jan 21, 2026, 8:00 AM EST - 4 weeks ago

Charles River Enters Manufacturing Collaboration with Gazi University

Jan 20, 2026, 3:39 PM EST - 4 weeks ago

Charles River Laboratories Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Charles River Laboratories International, Inc. - CRL

Jan 13, 2026, 3:55 PM EST - 5 weeks ago

Charles River Laboratories International, Inc. (CRL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 5:19 PM EST - 5 weeks ago

Charles River to buy Cambodia-based monkey supplier for $510 million

Jan 12, 2026, 4:30 PM EST - 5 weeks ago

Charles River Laboratories Provides Business Updates

Jan 8, 2026, 8:00 AM EST - 6 weeks ago

Charles River Laboratories Announces Planned Retirement of James C. Foster and CEO Succession Plan

Dec 11, 2025, 8:00 AM EST - 2 months ago

Charles River Extends Commitment to Advanced Therapy Developers with Second Incubator Program Cohort

Dec 4, 2025, 8:30 AM EST - 2 months ago

T. Rowe Price Transitions to Charles River's Enterprise Multi-Asset Investment Management Platform

Dec 3, 2025, 12:43 PM EST - 2 months ago

Charles River Laboratories International, Inc. (CRL) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 1, 2025, 3:42 PM EST - 2 months ago

HALPER SADEH LLC ENCOURAGES CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Dec 1, 2025, 8:00 AM EST - 3 months ago

Charles River Laboratories to Present at Evercore Healthcare Conference

Nov 21, 2025, 8:35 AM EST - 3 months ago

Madison Small Cap Fund Q3 2025 Portfolio Activity

EXP HXL SAIA

Nov 18, 2025, 12:58 PM EST - 3 months ago

Charles River Laboratories International, Inc. (CRL) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 18, 2025, 8:00 AM EST - 3 months ago

SOLVE and Charles River Development Partner to Deliver Integrated Fixed Income Pricing for Investment Managers

Nov 17, 2025, 8:00 AM EST - 3 months ago

Charles River Laboratories to Present at Jefferies Global Healthcare Conference

Nov 5, 2025, 2:21 PM EST - 3 months ago

Charles River Laboratories International, Inc. (CRL) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 1:38 PM EST - 3 months ago

Charles River Beat Expectations But Why Is The Stock Falling?

Nov 5, 2025, 12:33 PM EST - 3 months ago

Charles River: Mixed Q3 As Strategic Review Disappoints

Nov 5, 2025, 7:34 AM EST - 3 months ago

Charles River raises annual profit forecast on stabilizing biotech demand

Nov 5, 2025, 7:01 AM EST - 3 months ago

Charles River Laboratories Provides Update on Strategic Review

Nov 5, 2025, 7:00 AM EST - 3 months ago

Charles River Laboratories Announces Third-Quarter 2025 Results

Oct 22, 2025, 8:00 AM EDT - 4 months ago

Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development

Oct 20, 2025, 8:00 AM EDT - 4 months ago

Charles River and X-Chem Announce Strategic Collaboration to Enhance Hit Identification Capabilities

Oct 15, 2025, 8:00 AM EDT - 4 months ago

Charles River Announces Scientific Advisory Board to Drive Alternative Method Innovation and Adoption

Oct 14, 2025, 8:00 AM EDT - 4 months ago

Charles River Laboratories Schedules Third-Quarter 2025 Earnings Release and Conference Call

Oct 8, 2025, 8:00 AM EDT - 4 months ago

Charles River and Toxys Announce Collaboration to Validate the Use of NAMs for Developmental Toxicity Testing

Oct 7, 2025, 7:22 AM EDT - 4 months ago

Why Charles River Stock May Struggle In Its Final Phase

Sep 16, 2025, 7:05 AM EDT - 5 months ago

Charles River Laboratories Announces Chief Financial Officer Transition

Sep 11, 2025, 8:00 AM EDT - 5 months ago

Charles River Collaborates to Enhance Oncology Manufacturing Portfolio, Advancing Research and Development of Cell and Gene Therapies to Treat Cancer

Sep 10, 2025, 12:40 PM EDT - 5 months ago

Charles River Laboratories International, Inc. (CRL) Presents At Baird 2025 Global Healthcare Conference (Transcript)

Sep 9, 2025, 1:09 PM EDT - 5 months ago

Charles River Laboratories International, Inc. (CRL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 8:00 AM EDT - 6 months ago

Charles River Laboratories to Present at Baird and Morgan Stanley Conferences

Sep 3, 2025, 8:00 AM EDT - 6 months ago

Charles River Enhances Cell Therapy Flex Platform through Collaboration with Akadeum Life Sciences

Aug 26, 2025, 8:00 AM EDT - 6 months ago

Charles River Joins EASYGEN Consortium, Supports Development of Bedside CAR-T Manufacturing

Aug 6, 2025, 1:30 PM EDT - 7 months ago

Charles River Laboratories International, Inc. (CRL) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 12:50 PM EDT - 7 months ago

Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing

Aug 6, 2025, 12:47 PM EDT - 7 months ago

Charles River: Margin Fears Outweigh Solid Q2

Aug 6, 2025, 7:55 AM EDT - 7 months ago

Charles River raises profit forecast on growing demand for drug development services

Aug 6, 2025, 7:00 AM EDT - 7 months ago

Charles River Laboratories Announces Second-Quarter 2025 Results

Jul 22, 2025, 8:00 AM EDT - 7 months ago

Charles River Joins Elly's Team to Drive Rare Disease Gene Therapy Development

Jul 15, 2025, 8:00 AM EDT - 7 months ago

Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call

Jun 16, 2025, 8:00 AM EDT - 9 months ago

Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment

Jun 2, 2025, 8:00 AM EDT - 9 months ago

Charles River Laboratories to Present at William Blair and Jefferies Conferences

Estimize Feb. 23 at 3:00 PM

Wall St is expecting 1.93 EPS for $CRL Q1 [Reporting 05/07 BMO] http://www.estimize.com/intro/crl?chart=historical&metric_name=eps&utm_cont

0 · Reply

SuperGreenToday Feb. 23 at 10:04 AM

0 · Reply

Fletcher_13 Feb. 20 at 6:40 PM

$CRL 545k vol, staying flat until it commits toward 200.46 or rolls over

0 · Reply

RunnerSignals Feb. 20 at 11:31 AM

oversold bounce radar https://stocksrunner.com/news/2026-02-20-oversold-stocks-to-watch-today $CRL $ULS $ETSY $SMWB $PINS starting to wake up off the lows. setups getting interesting

0 · Reply

koditrump Feb. 18 at 7:19 PM

$CRL

0 · Reply

d_risk Feb. 18 at 3:53 PM

0 · Reply

ZacksResearch Feb. 18 at 3:07 PM

0 · Reply

ZacksResearch Feb. 18 at 1:11 PM

0 · Reply

StocktwitsEarnings Feb. 18 at 12:21 PM

0 · Reply

Estimize Feb. 18 at 11:00 AM

$CRL reported - EPS and - revenue for Q4. http://www.estimize.com/intro/crl?chart=historical&metric_name=eps&utm_content=CRL&utm_medium=act

0 · Reply

ZacksResearch Feb. 13 at 3:53 PM

$CRL Q4 Earnings: Will the past success repeat? 🤔 Despite a streak of earnings surprises, CRL's Q4 forecasts suggest a 1.7% revenue dip and a 12.4% EPS decline YoY. With a Zacks Rank #3 and negative Earnings ESP, an earnings beat seems unlikely this time. Full analysis here 👉 https://www.zacks.com/stock/news/2868912/heres-how-charles-river-stock-is-placed-ahead-of-q4-earnings?cid=sm-stocktwits-2-2868912-body-33529&ADID=SYND_STOCKTWITS_TWEET_2_2868912_BODY_33529

0 · Reply

ZacksResearch Feb. 13 at 2:53 PM

$CRL into Q4 — strength under the surface or cracks forming? 👀 The company heads into earnings backed by collaborations and solid momentum in RMS and Manufacturing, but DSA headwinds are weighing on revenue expectations. Mixed signals going into the print. Do the positives outweigh the pressure this quarter? Full setup ahead of Q4 👉 https://www.zacks.com/stock/news/2868912/heres-how-charles-river-stock-is-placed-ahead-of-q4-earnings?cid=sm-stocktwits-2-2868912-teaser-33525&ADID=SYND_STOCKTWITS_TWEET_2_2868912_TEASER_33525

0 · Reply

Sam201 Feb. 12 at 4:30 PM

$CRL Nice!!😊

0 · Reply

YouOnlyLiveTwice Feb. 11 at 5:25 PM

$CRL Medical device stocks are dead $$

0 · Reply

Arcides Feb. 11 at 5:11 PM

$CRL close to that level now

1 · Reply

Wallstfan Feb. 11 at 4:49 PM

$CRL on my watch list to buy. Waiting too see how earnings come in first.

0 · Reply

Estimize Feb. 11 at 2:01 PM

Wall St is expecting 2.35 EPS for $CRL Q4 [Reporting 02/18 BMO] http://www.estimize.com/intro/crl?chart=historical&metric_name=eps&utm_cont

0 · Reply

BillionerOfKing Feb. 10 at 12:32 PM

$CRL Current Stock Price: $185.64 Contracts to trade: $185.0 CRL Feb 20 2026 Call Entry: $9.54 Exit: $15.30 ROI: 60% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

SuperGreenToday Feb. 6 at 3:42 AM

$CRL Share Price: $183.51 Contract Selected: Jul 17, 2026 $160 Calls Buy Zone: $29.75 – $36.75 Target Zone: $48.97 – $59.85 Potential Upside: 55% ROI Time to Expiration: 161 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Arcides Feb. 5 at 5:33 PM

$CRL this is coming to 155 area.

0 · Reply

Sam201 Feb. 5 at 5:01 PM

$CRL finally!

0 · Reply

MerkleMarkets Feb. 4 at 11:07 AM

$CRL is a high-quality CRO but is exposed to biotech funding cycles, which have been weak, pressuring new order growth.

0 · Reply

Market Cap	8.32B
Revenue (ttm)	4.05B
Net Income (ttm)	22.20M
EPS (ttm)	N/A
PE Ratio	15.98
Forward PE	15.17
Profit Margin	0.55%
Debt to Equity Ratio	0.64

Volume	1,599,500
Avg Vol	885,062
Day's Range	N/A - N/A
Shares Out	49.23M
Stochastic %K	53%
Beta	1.63
Analysts	Strong Sell
Price Target	$203.14